ICU Medical (ICUI) Projected to Post Quarterly Earnings on Thursday

Key Points

• ICU Medical is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $1.44 per share and revenue of $543.33 million.
• The company's last earnings report showed strong performance with revenue of $599.49 million, surpassing analyst estimates and reflecting a 6.7% year-over-year increase.
• Recent insider activity includes significant stock sales by directors, with 1,942 shares sold by David C. Greenberg, reducing his holdings by 22.32%.

ICU Medical (NASDAQ:ICUI - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect ICU Medical to post earnings of $1.44 per share and revenue of $543.33 million for the quarter.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The company had revenue of $599.49 million during the quarter, compared to the consensus estimate of $574.15 million. During the same quarter in the prior year, the company posted $0.96 earnings per share. The firm's revenue for the quarter was up 6.7% on a year-over-year basis. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Down 0.8%

Shares of ICUI traded down $1.01 during trading hours on Friday, reaching $127.40. 242,242 shares of the stock traded hands, compared to its average volume of 180,698. ICU Medical has a 52 week low of $117.92 and a 52 week high of $196.26. The company has a current ratio of 2.59, a quick ratio of 1.52 and a debt-to-equity ratio of 0.75. The stock has a fifty day simple moving average of $130.62 and a 200 day simple moving average of $141.57. The company has a market cap of $3.14 billion, a price-to-earnings ratio of -33.26 and a beta of 0.88.

Insider Transactions at ICU Medical

In other news, Director Elisha W. Finney sold 600 shares of the company's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $138.92, for a total transaction of $83,352.00. Following the transaction, the director owned 3,252 shares of the company's stock, valued at $451,767.84. This represents a 15.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 5,556 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $138.65, for a total value of $770,339.40. Following the transaction, the chief operating officer owned 2,389 shares of the company's stock, valued at $331,234.85. The trade was a 69.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,097 shares of company stock worth $4,860,156 in the last ninety days. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On ICU Medical

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock worth $1,297,000 after acquiring an additional 229 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ICU Medical by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier's stock valued at $1,772,000 after purchasing an additional 560 shares during the last quarter. United Services Automobile Association bought a new position in shares of ICU Medical during the 1st quarter valued at $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in ICU Medical by 32.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier's stock valued at $9,472,000 after purchasing an additional 16,680 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier's stock worth $1,658,000 after acquiring an additional 3,326 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ICUI shares. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James Financial cut their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday, May 9th. KeyCorp lowered their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Finally, Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday, May 18th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICU Medical has a consensus rating of "Buy" and a consensus target price of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.